VTRSViatris

1. Oct 8, 2026Agreement and Plan of Merger On October 8, 2026, Viatris Inc., a Delaware corporation (“Viatris”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Pacira BioSciences, Inc., a Delaware corporation (“Pacira”), and Peach Purchaser Sub Inc., a Delaware corporation and a wholly owned subsidiary …Material agreement entered · Form 8-K
2. Aug 6, 2026As previously announced, Viatris will host a conference call and live webcast today at 8:30 a.m. ET to review the Company's financial results for the period ended June 30, 2026.Earnings release · Form 8-K
3. Jul 1, 2026On July 1, 2026 (the “Closing Date”), Viatris Inc. (“Viatris”) entered into an amended and restated term loan credit agreement (the “Amended and Restated Term Loan Credit Agreement”), among Viatris, the guarantors from time to time party thereto, the lenders from time to time party thereto and Mizuho Bank, Ltd., as …Material agreement entered · Form 8-K
4. Jun 18, 2026On June 17, 2026, Viatris Inc. (“Viatris” or the “Company”) completed a public offering of €650,000,000 aggregate principal amount of its 4.250% Senior Notes due 2033 (the “Notes”)Material agreement entered · Form 8-K
5. Jun 15, 2026On June 12, 2026, Viatris Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with the several underwriters named in Schedule I thereto, for whom BNP PARIBAS, Citigroup Global Markets Limited and Goldman Sachs & Co. LLC are acting as representatives, to issue and sell (the …Other event · Form 8-K
6. May 7, 2026As previously announced, Viatris will host a conference call and live webcast today at 8:30 a.m. ET to review the Company's financial results for the period ended March 31, 2026.Earnings release · Form 8-K
7. May 4, 2026On May 1, 2026, Theodora (“Doretta”) Mistras informed Viatris Inc. (the “Company”) that she would voluntarily cease to serve as Chief Financial Officer to pursue another professional opportunity.Director or officer change · Form 8-K
8. Feb 26, 2026In 2025, Viatris initiated an enterprise-wide strategic review (“EWSR”) to enable the Company to build a more focused, efficient and future-ready organization and position the Company for sustained growth beginning in 2026.Earnings release · Form 8-K
9. Feb 3, 2026On February 3, 2026, Viatris Inc. (the “Company”) announced that Brian Roman, Chief Legal Officer of the Company, would transition from his role with the Company and cease to serve as Chief Legal Officer effective as of February 9, 2026.Director or officer change · Form 8-K
10. Dec 8, 2025Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited.Regulation FD disclosure · press release

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.